Table 2.
Recommended pharmacological therapies for the hypothetical patient vignette
| Drug | Number and percentage of respondentsa (n = 200) | Number and percentage of respondentsa (n = 79) | Signif. | ||||
|---|---|---|---|---|---|---|---|
| 2006 | 2013 | ||||||
| n | % | 95 % CI | n | % | 95 % CI | ||
| Paracetamol (including slow release option) | 190 | 95 | 91–97 | 72 | 91 | 83–96 | 0.349 |
| Oral NSAID (conventional or COX-2 selective) | 160 | 80 | 74–85 | 66 | 84 | 74–91 | 0.610 |
| Topical NSAID (conventional or COX-2 selective) | 19 | 10 | 6–14 | 1 | 1 | 0–6 | 0.032 |
| Tramadol | 29 | 15 | 10–20 | 24 | 30 | 21–42 | 0.004 |
| Opioids–paracetamol plus codeine | 28 | 14 | 9–20 | 14 | 18 | 10–28 | 0.550 |
| Opioids–codeine | 65 | 33 | 26–39 | 5 | 6 | 2–14 | <0.001 |
| Opioids–oxycodone, morphine or buprenorphine | 10 | 5 | 3–9 | 16 | 20 | 12–31 | <0.001 |
| Intra-articular injections | 12 | 6 | 4–10 | 8 | 10 | 5–19 | 0.344 |
| Glucosamine and/or chondroitin | 78 | 39 | 33–46 | 10 | 13 | 6–22 | <0.001 |
| Fish or krill oil | 11 | 6 | 3–9 | 10 | 13 | 7–22 | 0.074 |
aRespondents may have more than one response